Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection - comparison with omeprazole and lansoprazole
Autore:
Miwa, H; Ohkura, R; Murai, T; Sato, K; Nagahara, A; Hirai, S; Watanabe, S; Sato, N;
Indirizzi:
Juntendo Univ, Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138421, Japan Juntendo Univ Tokyo Japan 1138421 terol, Bunkyo Ku, Tokyo 1138421, Japan Juntendo Univ, Sch Med, Dept Pathol, Tokyo 1138421, Japan Juntendo Univ Tokyo Japan 1138421 Med, Dept Pathol, Tokyo 1138421, Japan
Titolo Testata:
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
fascicolo: 6, volume: 13, anno: 1999,
pagine: 741 - 746
SICI:
0269-2813(199906)13:6<741:IORANP>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
IN-VITRO; UREASE INHIBITION; PANTOPRAZOLE; AMOXICILLIN; CLARITHROMYCIN; METABOLISM; EFFICACY; GROWTH; E3810;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Sato, N Juntendo Univ, Sch Med, Dept Gastroenterol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan Juntendo Univ 2-1-1 Hongo Tokyo Japan 1138421 okyo 1138421, Japan
Citazione:
H. Miwa et al., "Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection - comparison with omeprazole and lansoprazole", ALIM PHARM, 13(6), 1999, pp. 741-746

Abstract

Background: A recent trend in curative therapy for Helicobacter pylori infection is the so-called triple therapy, which consists of a proton pump inhibitor (PPI) and two different antimicrobials. Various regimens employing this triple therapy have been reported. However, little is known about the effectiveness of rabeprazole, a recently developed proton pump inhibitor, when used in the triple therapy. Aim: To validate its usefulness by comparing rabeprazole with omeprazole and lansoprazole, in combination with amoxycillin and clarithromycin. Patients and methods: 221 H. pylori-positive patients with peptic ulcer disease were randomized to receive one of three different proton pump inhibitor/amoxycillin-clarithromycin (PPI/AC) regimens for 7 days. (i) OAC regimen(n = 75): omeprazole 20 mg b.d., amoxycillin (AMOX) 500 mg t.d.s. and clarithromycin (CAM) 200 mg b.d.; (ii) LAC regimen (n = 74): lansoprazole 30 mgb.d., AMOX 500 mg t.d.s. and CAM 200 mg b.d.; and (iii) RAC regimen (n = 72): rabeprazole 20 mg b.d., AMOX 500 mg t.d.s. and CAM 200 mg b.d. Cure of the infection was determined by the C-13 urea breath test 1 month after completion of the treatment. Results: Intention-to-treat based cure rates for OAC, LAC and RAC regimenswere 85% (95% CI, 75-92), 84% (95%, CI 73-91) and 88% (95% CI, 78-94), respectively, and per protocol based cure rates of these regimens were 88% (95% CI, 78-94), 91% (95%, CI 82-99) and 93% (95% CI, 84-98), respectively. Adverse effects in the entire study population, which included diarrhoea, glossitis or skin rash, were reported by 15% of the patients, and complete compliance was achieved in 95% of these patients. Conclusion: 1-week proton pump inhibitor/AC regimens for H. pylori infection were effective in the Japanese population. Rabeprazole can be consideredas equivalent to omeprazole and lansoprazole in the PPI/AC triple therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/07/20 alle ore 05:57:25